Learn how Sciomics supports COVID-19 research!



Sciomics is a Heidelberg-based CRO with a focus on Multiplex Protein Analyses.

Which COVID-19 research topics can be addressed by Sciomics?

- In-depth protein analysis for improved disease management of COVID-19
 - > Immune response profiling and characterization of patient cohorts
 - > Identification of disease severity biomarkers for patient stratification
 - > Assessment of severe COVID-19 risk factors for improved patient outcome
- Development of new therapeutics against COVID-19
 - > Compounds benchmarking by pathway activity, early toxicology and mechanisms of action analysis (cell culture and animal models)
 - > Assessment of treatment response and identification of predictive biomarkers
- Development of vaccines against SARS-CoV-2
 - > In-depth analysis of vaccination response in animal and patient samples
 - > Characterization of animal models (mouse, rat and others)
 - > Identification of **highly immunogenic epitopes** in COVID-19 survivors

Which assays are offered by Sciomics?

scioCD: 121 cytokines and 141 cell surface markers for immune profiling

of plasma/serum, immune cell or tissue samples

• scioDiscover: 1300 proteins including inflammatory mediators, immune

checkpoint molecules, immune cell markers as well as further

membrane/receptor and intracellular proteins for

biomarker discovery on plasma/serum, cell or tissue samples

• scioPhospho: combined phosphorylation and expression profiling of 1300 proteins

for signaling activity profiling on cell or tissue samples

> All assays can be complemented by a SARS-CoV-2 proteome wide peptide array.

Assay specifics

- Minimal sample amount required (20 µl of plasma/serum, 500 000 cells, 10 mg of tissue)
- Complete analysis service from sample to study report





